Phase II study of Neoadjuvant chemotherapy with Gemcitabine and S1 for resectable pancreatic carcinoma
Phase 2
- Conditions
- resectable pancreatic cancer
- Registration Number
- JPRN-UMIN000004148
- Lead Sponsor
- Study group of preoperative therapy for pancreatic cancer (Prep)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1) pulmonary fibrosis or interstitial pneumonitis 2) tumor other than ductal carcinoma 3) distant metastasis 4) R2 resection 5) prior anti-cnacer therapy 6) pregnancy 7) under 20 years old
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2 year survival rate
- Secondary Outcome Measures
Name Time Method Adverse effect, resectability rate, residual tumor(R), nodal involvement(N), pathological effect, recurrence free survival, tumor marker, dose intensity